Atrium Therapeutics Inc.
RNA | NASDAQ
$8.27
+$0.01 (+0.12%)
At close: Oct 30, 2026, 4:00 PM ET
$8.22
-$0.05 (-0.60%)
Pre-market:
Nov 2, 2026, 9:28 AM ET
Company Profile
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Kathleen Gallagher | President, CEO & Director |
| Brendan Winslow | Chief Financial Officer |
| Husam Younis | Chief Scientific Officer |
| Rocio Martin Hoyos | Chief Strategy Officer |
| Stephanie Kenney | Chief Corporate Affairs Officer |
| Steven George Hughes | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Atrium Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 27, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 511 |
| CEO | Kathleen Gallagher |
Contact Details
10578 Science Center Drive San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | RNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002093101 |
| CUSIP Number | 04965N104 |
| ISIN Number | US04965N1046 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove RNA